Jules Adam

France

Junior Reporter at Labiotech

Featured in: Favicon

labiotech.eu Favicon

uaebusinessdaily.com

Articles

What happened to COVID vaccine companies?

1 week ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility.
The past, present, and future of genome sequencing

2 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. Genome sequencing is the process of determining the complete DNA sequence of an organism’s genome, a step-by-step decoding of all the genetic instructions.
Tariffs and trade war: A guide for expanding biotech business internationally

3 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
Tariffs and trade war: A guide for expanding biotech business internationally

3 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Biotech companies have always been global at their core. From running clinical trials across continents to delivering therapies internationally, success in these industries also depends on crossing borders seamlessly.
These are the HIV therapeutics startups to watch in 2025

4 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Over four decades since its discovery, human immunodeficiency virus (HIV) remains one of the most challenging infectious diseases.
Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases

4 weeks ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. A fresh take on gene-editing, centered on engineered recombinases, emerges as Brink Therapeutics, a Paris-based biotech startup, secures €3.5 million ($4 billion) in seed funding to advance its platform.
The metabolomics revolution: Why biotech leaders should pay attention

1 month ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. For decades, biology has spoken three main languages: DNA, RNA, and proteins. These fields – genomics, transcriptomics, and proteomics – are now deeply integrated into both research and the clinic.
The biotech job market in 2025: Still in survival mode?

1 month ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. After a tough period of layoffs and hiring freezes, many were hoping 2025 would bring some relief to the biotech job market. But so far, that rebound hasn’t quite arrived.
Is space the new frontier for biotech? Exobiosphere lands €2M to accelerate drug discovery beyond Earth

1 month ago | labiotech.eu | Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. Do you associate biotech with space conquest? Space isn’t just about rockets and satellites – it’s an increasingly valuable environment for running biomedical experiments that aren’t possible on Earth.
Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

1 month ago | labiotech.eu | Ryoji Iwata |Jules Adam

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Alzheimer’s disease affects more than 55 million people worldwide — a number expected to nearly triple by 2050.